As the Most-Favored-Nation (MFN) drug pricing policy progresses, the implications for global launch strategies are becoming clearer.

Building on his previous insights, Tim Wright, Executive Vice President for Access and Pricing at Genesis Research Group, provides an essential update on the three demonstration models underpinning the policy: GENEROUS, GUARD and GLOBE.

Tim discusses the current state of GENEROUS, including why the White House’s headline savings figures do not add up as simply as they first appear. He explains why GUARD and GLOBE have been delayed, what over 20,000 public responses mean for the final policy, and which drug categories may end up exempt.

The conversation also covers new survey findings on how international payers expect manufacturers to respond, plus the practical mitigation strategies companies are already building, from launch sequencing to subpopulation pricing.

Drawing on his work with manufacturers responding to MFN, Tim offers a practical perspective on the latest policy developments and their implications for global pricing and market access strategies.

Please contact us if you have questions or would like a copy of the slides.

Explore our Access & Pricing Solutions

About the presenter

Tim Wright leads the Access & Pricing division at Genesis Research Group. An economist and health economist, Tim has 30 years of experience in the biopharma sector, including 18 years in executive positions in strategic consulting firms and 12 years in global EU and UK roles in industry. In consulting, Tim has provided strategic leadership in over 1000 engagements with small biotechs to top-five pharma and across all therapy areas. Within the industry, Tim was responsible for global pricing and access strategy for two mega-brands and the CV, respiratory, infection and inflammation early asset portfolio at AstraZeneca. He is former Head of HEOR at Janssen Cilag UK, and brings experience from EU Pricing for Allergan and his time as a clinical scientist at Astra.